Critical Therapeutics Inc (fka CRTX)

[dinogreeves]

We could potentially hit $70.00 tomorrow.

[crudeoil24]

Heading back to December high of $76. next week.

CRTX

[crudeoil24]

Definitely great trading > CRTX

[Alan Brown]

$100 was not reached yet.

[Alan Brown]

Well it didnt even break through and stayed at 80 or 90

[crudeoil24]

$60.00 in AH > ( brush & floss your teeth )

Porphyromonas gingivalis, or P. gingivalis, most commonly associated with chronic periodontal disease, and its secreted proteases called gingipains can infiltrate the brain and cause AD.

CRTX

[crudeoil24]

"Porphyromonas gingivalis, or P. gingivalis, most commonly associated with chronic periodontal disease, and its secreted proteases called gingipains can infiltrate the brain and cause AD. "

[crudeoil24]

Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat what it believes to be a key underlying cause of Alzheimer’s and other degenerative diseases, today announced Casey Lynch, the company’s chief executive officer, chair, and co-founder will present at the 3rd Annual Neuroscience Innovation Forum on Sunday, January 12, 2020 at 3:45 p.m. PST / 6:45 p.m. EST. The Forum will take place on the eve of the J.P. Morgan Healthcare Conference in downtown San Francisco.

[jimmy667]

Seems to be manipulated for the connected hedge funds to take advantage of retail investors.

[crudeoil24]

" We are a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat what we believe to be a key underlying cause of Alzheimer’s and other degenerative diseases. Our approach is based on the seminal discovery of the presence of Porphyromonas gingivalis, or P. gingivalis, and its secreted toxic virulence factor proteases, called gingipains, in the brains of greater than 90% of more than 100 Alzheimer’s patients observed across multiple studies to date. Additionally, we have observed that P. gingivalis infection causes Alzheimer’s pathology in animal models, and these effects have been successfully treated with a gingipain inhibitor in preclinical studies. Our proprietary lead drug candidate, COR388, is an orally-administered, brain-penetrating small molecule gingipain protease inhibitor. COR388 was well-tolerated with no concerning safety signals in our Phase 1a and Phase 1b clinical trials conducted to date, which enrolled a total of 67 subjects, including nine patients with mild to moderate Alzheimer’s disease. We plan to initiate a global Phase 2/3 clinical trial of COR388, called the GAIN trial, in mild to moderate Alzheimer’s patients in the second quarter of 2019 and expect top-line results by the end of 2021."

SEC S-1 > 4/12/19

[crudeoil24]

Lamond Trust owns 2.8M shares as recorded in SEC 13G dated 9/30/19.

[crudeoil24]

Blue Devil Trust owns 1.9M shares as recorded in SEC 13G dated 9/30/19.

[Oger]

Why does this keep rising on no recent news?

[INTL]

Very possible. These guys are on the verge. Also a big fan of one of Friday’s big AH movers as another future power player in this space. Similar amazing chart. Best of Luck!

[Oger]

Based on what?

[dinogreeves]

CRTX 150 plus dollars next week.

[eur06]

What a miss!
I wish had payed more attention last week.
Great for whoever made $$$$ !!!!!

[crudeoil24]

75.40 in AH.> 150+ coming next week. What a Christmas present!

[grich1]

It’s over $70 bucks AH. $100 will be here real quick. I researched this company when it was private and I missed the IPO but I’m glad I bought some when I did. I didn’t expect this run.

[crudeoil24]

I agree. Expecting to run in the 100's. POWERHOUSE CRTX

[crudeoil24]

Massive 800,000 shares bought in last few minutes.

[grich1]

Someone stepped in and made a big purchase. Pfizer is not going to be the only company making a profit.

Sweet run. Low float is going to put this over $100 as the company has zero need to dilute.

[crudeoil24]

67.50 > new hod!

[crudeoil24]

Looking @ 60.00+ @ closing bell!

[crudeoil24]

58.24 > running on very low volume. > 9M float.

[dinogreeves]

Definitely possible.

[grich1]

Looks like it might get there today.

[grich1]

Looks like I didn’t buy enough.
I will add. Great run.
The evidence is mounting and this looks like the only player in town.

[crudeoil24]

Alzheimers > After 28 days, a statistically significant decrease in ApoE fragments was observed in subjects treated with COR388 versus those treated with placebo.



Pfizer and Takeda are on board with CRTX. Each own 10% of the OS.

[dinogreeves]

Valuation could reach 1.5 billion before the end of the year.

[crudeoil24]

55.55 > double nickels × 2

[dinogreeves]

Already broke 52 week high.

[crudeoil24]

53.00 >

[crudeoil24]

48.87 > 52 week new high!

[crudeoil24]

Boom! ...46.51

[crudeoil24]

44.75

[crudeoil24]

44.07

[crudeoil24]

43.10

[crudeoil24]

9M float > looking @ $50.+ by Friday 12/20.

[crudeoil24]

Possibly more large pharma & tutes jumping on board.....

Pfizer and Takeda are on board with CRTX. Each own 10% of the OS.

[crudeoil24]

Very revealing: “Recent research has shown that the APOE gene may play a larger role than previously believed in Alzheimer’s disease development, suggesting that a solid understanding of APOE is important to a comprehensive hypothesis of Alzheimer’s causation,” said Casey Lynch, Cortexyme’s chief executive officer, co-founder, and chair, and a co-author of today’s presentation. “We believe the data presented today provide insight into why APOE4 increases the risk for Alzheimer’s disease: the ApoE4 protein, which is important for synaptic maintenance and control of neuroinflammation, has a higher propensity to be fragmented by gingipains, compared to other forms of ApoE. Importantly, our human studies have shown the ability of COR388 to protect ApoE proteins from gingipain fragmentation in the brains of study subjects.”

A growing body of evidence points to P. gingivalis as playing a key role in the development of Alzheimer’s disease given its identification in the brains of AD patients and its ability to cause neurodegeneration, inflammation, beta-amyloid and tau buildup, and other pathology associated with the disease in animal models. An asacchrolytic bacterium, P. gingivalis has been shown to infiltrate the brain and release toxic proteases called gingipains that cleave ApoE, tau, and other proteins associated with neuronal function. Cortexyme is developing COR388, an investigational small-molecule gingipain inhibitor that is currently in a large, international Phase 2/3 clinical trial (the GAIN Trial). This trial is evaluating the efficacy, safety, and tolerability of COR388 in patients with mild to moderate AD, with top-line results expected in the fourth quarter of 2021.

[crudeoil24]

39.05 > CRTX is a great $$$$$ opportunity.

[crudeoil24]

38.68

[crudeoil24]

38.01 > CRTX

[dinogreeves]

Solid stock with great fundamentals.

[crudeoil24]

37.54 > Boomtown USA > MAGA & MEGA MOVES > CRTX

[crudeoil24]

Easy $40.+ > big block buys taking CRTX to 52 week highs!

[crudeoil24]

Nice having Pfizer on board here.

Pfizer and Takeda are on board with CRTX. Each own 10% of the OS.

[crudeoil24]

36.17 > CRTX > Onwards and upwards!

[crudeoil24]

Continuous upside moves. Possible 40.00+ late session.

CRTX